8 Jul 2021 15:13
Immunodiagnostic Systems Holdings PLC
Exercise of options
08 July 2021
Immunodiagnostic Systems Holdings PLC ("IDS" or the "Company") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that, on 8 July 2021, 169,350 share options were exercised by directors and employees of the Company.
A total of 169,350 new ordinary shares of 2p each in the Company ("Ordinary Shares") have been transferred from treasury stock for the purpose of satisfying the exercise of the share options.
As noted in the announcement on 18 May 2021, these options have been exercised in full shortly prior to the scheme of arrangement to be implemented to effect the recommended cash offer for IDS by PerkinElmer (UK) Holdings Ltd becoming effective.
Total voting rights
Following the above transfer of treasury stock, the Company's issued share capital comprises 29,411,175 Ordinary Shares. Of these 457,728 are held in Treasury. The total voting rights of the Company are 28,953,447 Ordinary Shares and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the number of options exercised by PDMRs.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 519 0660 |
Paul Martin, Group Finance Director
|
|
|
|
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel |
|
Victoria Erskine |
|
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||||||||||||||||||||||||||||||||||
a. | Name | 1. Jaap Stuut 2. Paul Martin 3. Nicola Trewin 4. Soenke Weissenborn | |||||||||||||||||||||||||||||||||||||||||
2. | Reason for the notification | ||||||||||||||||||||||||||||||||||||||||||
a. | Position/status | 1. Chief Executive Officer 2. Group Finance Director 3. Group HR Director 4. Group Operations Director | |||||||||||||||||||||||||||||||||||||||||
b. | Initial notification /Amendment | Initial | |||||||||||||||||||||||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||||||||||||||||||||||||||||
a. | Name | Immunodiagnostic Systems Holdings plc | |||||||||||||||||||||||||||||||||||||||||
b. | LEI | 213800HZMYTD4NGF4L78 | |||||||||||||||||||||||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||||||||||||||||||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc
Ordinary shares
GB00B01YZ052 | |||||||||||||||||||||||||||||||||||||||||
b. | Nature of the transaction | Exercise of Options
| |||||||||||||||||||||||||||||||||||||||||
c. | Price(s) and volume(s) |
| |||||||||||||||||||||||||||||||||||||||||
d. | Aggregated information ·Aggregated volume ·Price
|
| |||||||||||||||||||||||||||||||||||||||||
e. | Date of the transaction | 08-July-21 | |||||||||||||||||||||||||||||||||||||||||
f. | Place of the transaction | Outside a trading venue | |||||||||||||||||||||||||||||||||||||||||